Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against .ALPHA.-Fas-Induced Liver Injury in a Mouse Model
スポンサーリンク
概要
- 論文の詳細を見る
In a mouse model of α-Fas-induced acute liver injury, the orally-administered caspase inhibitor PF-03491390 (formerly named IDN-6556) was retained in the liver for prolonged periods with a low systemic exposure. Reductions in the elevated plasma levels of alanine aminotransferase (ALT) revealed that the retention of PF-03491390 in the liver exerted a hepatoprotective effect, even when pre-administered to mice 4 h before α-Fas insult. Prolonged retention of PF-03491390 in the liver after oral administration has the benefit of low systemic exposure, making this a beneficial agent for the treatment of liver diseases.
- 公益社団法人 日本薬理学会の論文
著者
-
Ohmi Takashi
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Kato Naoto
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Eda Hiroyuki
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Kojima Midori
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Ueno Yoshinobu
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Matsuura Tomomi
Pharmacokinetics Dynamics & Metabolism Global Research & Development Nagoya Laboratories Pfi
-
Moriguchi Yukiko
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Yamamoto Mitsuko
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Suzuki Sachiko
Pharmacokinetics Dynamics & Metabolism Global Research & Development Nagoya Laboratories Pfi
-
Eda Hiroyuki
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Shimozono Rieko
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Ueno Yoshinobu
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Yamamoto Mitsuko
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Ohmi Takashi
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Matsuura Tomomi
Pharmacokinetics, Dynamics & Metabolism, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
関連論文
- Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model
- Contribution of Active and Inactive States of the Human 5-HT_ Receptor to the Functional Activities of 5-HT_4-Receptor Agonists
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against .ALPHA.-Fas-Induced Liver Injury in a Mouse Model